Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)

3 Months Ended

Feb. 29, 2016

Stock option activity for the three months ended February 29, 2016, was as follows:


	Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding at November 30, 2015		968,930	$	2.17		5.01	$	1,095,525

Granted		—		—				—
Exercised		—		—				—
Expired/forfeited		—		—				—

Outstanding at February 29, 2016		968,930	$	2.17		4.76	$	1,531,543

Exercisable at February 29, 2016		959,552	$	2.16		4.75	$	1,525,260

Significant Option Groups Exercisable Option and its Price and Contractual Life

Significant option groups exercisable at February 29, 2016 and related price and contractual life information are as follows:


	Outstanding						Exercisable
Range of Exercise Prices	Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Outstanding		Weighted Average Exercise Price
$1.01 to $2.00		465,930		5.23	$	1.72		465,930	$	1.72
$2.01 to $3.00		480,500		4.23	$	2.56		480,500	$	2.56
$3.01 to $4.00		22,500		6.36	$	3.08		13,122	$	3.08

		968,930		4.76	$	2.17		959,552	$	2.16

Summary of Non-Vested Options

A summary of the status of the Company’s non-vested options as of February 29, 2016, and changes during the three months ended February 29, 2016, is presented below:


	Options			Weighted Average Grant-Date Fair Value
Non-vested at November 30, 2015		15,003		$	1.90

Granted		—			—
Vested		(5,625	)		1.90
Forfeited		—			—

Non-vested at February 29, 2016		9,378		$	1.90